This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/kegg-compound/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/bindingdb/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/kegg-drug/
n12http://www.drugs.com/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/drugbank/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/ontology/sukl/drug/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01420/identifier/pharmgkb/

Statements

Subject Item
n2:DB01420
rdf:type
n3:Drug
n3:description
An ester of testosterone with a propionate substitution at the 17-beta position. [PubChem]
n3:group
approved
n3:indication
Testosterone propionate is an anabolic steroid and a short ester form of testosterone that becomes active in the body. It is often used for muscle mass building.
owl:sameAs
n15:DB01420 n16:DB01420
dcterms:title
Testosterone Propionate
adms:identifier
n8:PA164751373 n17:46508693 n18:D00959 n19:5995 n20:DB01420 n21:C08158 n22:50215709 n23:5774
n3:mechanismOfAction
The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
n3:packager
n5:271B48B4-363D-11E5-9242-09173F13E4C5 n5:271B48B7-363D-11E5-9242-09173F13E4C5 n5:271B48B8-363D-11E5-9242-09173F13E4C5 n5:271B48B5-363D-11E5-9242-09173F13E4C5 n5:271B48B6-363D-11E5-9242-09173F13E4C5 n5:271B48B9-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form.
n3:synonym
Testex
n3:toxicity
Side effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.
n9:hasAHFSCode
n10:68-08-00
n3:proteinBinding
40% of testosterone in plasma is bound to sex hormone-binding globulin and 2% remains unbound and the rest is bound to albumin and other proteins.
foaf:page
n12:testosterone.html
n3:IUPAC-Name
n4:271B48C0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48C6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48C5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B48C2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48C3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48C4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B48BE-363D-11E5-9242-09173F13E4C5 n4:271B48D6-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B48BC-363D-11E5-9242-09173F13E4C5 n4:271B48BF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B48BD-363D-11E5-9242-09173F13E4C5 n4:271B48D8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B48CC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B48CD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48C7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48C8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B48CA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B48C9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B48CB-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
57-85-2
n3:containedIn
n13:271B48BB-363D-11E5-9242-09173F13E4C5 n13:271B48BA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B48D2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B48D4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B48D5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B48D7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B48D1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B48D0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B48D3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B48C1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B48CE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B48CF-363D-11E5-9242-09173F13E4C5